Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.

Saved in:
Bibliographic Details
Title: Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
Authors: Lockman S; Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana. Electronic address: slockman@hsph.harvard.edu., Brummel SS; Center for Biostatistics in AIDS Research, Harvard TH Chan School of Public Health, Boston, MA, USA., Ziemba L; Center for Biostatistics in AIDS Research, Harvard TH Chan School of Public Health, Boston, MA, USA., Stranix-Chibanda L; College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe., McCarthy K; FHI 360, Durham, NC, USA., Coletti A; FHI 360, Durham, NC, USA., Jean-Philippe P; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Johnston B; Frontier Science Foundation, Amherst, NY, USA., Krotje C; Frontier Science Foundation, Amherst, NY, USA., Fairlie L; Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Hoffman RM; David Geffen School of Medicine, Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, CA, USA., Sax PE; Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, USA., Moyo S; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Chakhtoura N; Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA., Stringer JS; Division of Global Women's Health, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Masheto G; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Korutaro V; Baylor College of Medicine Children's Foundation, Kampala, Uganda., Cassim H; Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Mmbaga BT; Kilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical Centre and Kilimanjaro Christian Medical University College, Moshi, Tanzania., João E; Hospital Federal dos Servidores do Estado, Rio de Janeiro, Brazil., Hanley S; Centre for the AIDS Programme of Research in South Africa, University of KwaZulu-Natal, Umlazi, South Africa., Purdue L; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Holmes LB; MassGeneral Hospital for Children, Boston, MA, USA., Momper JD; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, USA., Shapiro RL; Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA; Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana., Thoofer NK; ViiV Healthcare, Brentford, Middlesex, UK., Rooney JF; Gilead Sciences, Foster City, CA, USA., Frenkel LM; Department of Pediatrics, Department of Laboratory Medicine, Department of Global Health, and Department of Medicine, University of Washington, and Seattle Children's Research Institute, Seattle, WA, USA., Amico KR; Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI, USA., Chinula L; Division of Global Women's Health, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; UNC Project Malawi, Lilongwe, Malawi., Currier J; David Geffen School of Medicine, Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, CA, USA.
Corporate Authors: IMPAACT 2010/VESTED Study Team and Investigators
Source: Lancet (London, England) [Lancet] 2021 Apr 03; Vol. 397 (10281), pp. 1276-1292.
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(21)00314-7